Picton Mahoney Asset Management bought a new position in Moderna, Inc. (NASDAQ:MRNA) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 9,921 shares of the company’s stock, valued at approximately $2,331,000.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. HighTower Advisors LLC lifted its position in Moderna by 34.1% in the first quarter. HighTower Advisors LLC now owns 44,946 shares of the company’s stock worth $5,889,000 after purchasing an additional 11,440 shares during the period. Swiss National Bank lifted its position in Moderna by 9.9% in the first quarter. Swiss National Bank now owns 1,146,100 shares of the company’s stock worth $150,082,000 after purchasing an additional 103,200 shares during the period. Maryland State Retirement & Pension System lifted its position in Moderna by 17.0% in the second quarter. Maryland State Retirement & Pension System now owns 25,561 shares of the company’s stock worth $5,964,000 after purchasing an additional 3,709 shares during the period. Rhumbline Advisers lifted its position in Moderna by 8.4% in the second quarter. Rhumbline Advisers now owns 346,291 shares of the company’s stock worth $81,371,000 after purchasing an additional 26,740 shares during the period. Finally, Bamco Inc. NY increased its holdings in shares of Moderna by 1,062.7% in the first quarter. Bamco Inc. NY now owns 44,182 shares of the company’s stock valued at $5,786,000 after buying an additional 40,382 shares in the last quarter. Hedge funds and other institutional investors own 55.89% of the company’s stock.
Several research analysts have issued reports on MRNA shares. Argus upped their price target on Moderna from $200.00 to $230.00 and gave the company a “buy” rating in a report on Thursday, June 24th. Chardan Capital reaffirmed a “buy” rating on shares of Moderna in a report on Wednesday, July 7th. Zacks Investment Research cut Moderna from a “buy” rating to a “hold” rating and set a $330.00 price target on the stock. in a report on Monday, July 19th. TheStreet downgraded shares of Moderna from a “b” rating to a “c+” rating in a research note on Friday, June 11th. Finally, Oppenheimer downgraded shares of Moderna from an “outperform” rating to a “market perform” rating in a research note on Thursday, August 5th. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $205.21.
Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Thursday, August 5th. The company reported $6.46 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $6.01 by $0.45. Moderna had a net margin of 49.79% and a return on equity of 88.13%. The company had revenue of $4.35 billion during the quarter, compared to analysts’ expectations of $4.23 billion. During the same period in the prior year, the company earned ($0.31) earnings per share. The business’s quarterly revenue was up 6457.2% compared to the same quarter last year. On average, sell-side analysts forecast that Moderna, Inc. will post 29.17 earnings per share for the current fiscal year.
In other Moderna news, insider Tal Zvi Zaks sold 5,000 shares of the company’s stock in a transaction dated Wednesday, June 30th. The shares were sold at an average price of $237.00, for a total transaction of $1,185,000.00. Following the completion of the sale, the insider now directly owns 5,000 shares in the company, valued at $1,185,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Stephane Bancel sold 9,000 shares of the company’s stock in a transaction dated Wednesday, September 15th. The shares were sold at an average price of $427.13, for a total transaction of $3,844,170.00. The disclosure for this sale can be found here. Insiders have sold 315,000 shares of company stock valued at $111,396,920 over the last 90 days. Corporate insiders own 19.40% of the company’s stock.
Moderna Company Profile
Moderna, Inc engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.
Featured Article: What is the yield curve?
Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA).
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.